American Well (AMWL) Q2 Revenue Up 13%

American Well (AMWL) reported strong Q2 2025 results, with GAAP revenue of $70.9 million surpassing analyst estimates by 11.7% and adjusted EBITDA loss narrowing significantly to $(4.7) million, an 86.6% year-over-year improvement, alongside a record 56.1% gross margin. The company's strategic pivot towards high-margin software subscription revenue is evident, despite lowering full-year 2025 revenue guidance to $245-$250 million due to a psychiatric care segment divestiture. Key client wins and an extended Defense Health Agency contract reinforce AMWL's shift to a more predictable, software-centric model, supporting its target of positive cash flow from operations by 2026.

Analysis

American Well's (AMWL) Q2 2025 results signal a successful execution of its strategic pivot towards a higher-margin, software-centric business model. The company reported GAAP revenue of $70.9 million, surpassing analyst consensus by 11.7%, and achieved a record gross margin of 56.1%. More critically, the adjusted EBITDA loss narrowed substantially to $(4.7) million, an 86.6% year-over-year improvement that dramatically beat estimates. This enhanced profitability is directly attributable to the growth in subscription revenue, which reached $40.4 million and is on track to comprise nearly 60% of total revenue in 2025. While the full-year revenue guidance was revised downward to $245-$250 million, this reflects the strategic divestiture of its psychiatric care segment, not a deterioration in the core business. This is further validated by the improved full-year adjusted EBITDA loss guidance, now projected at $(50) to $(45) million. Key contract wins, including Florida Blue and an extension with the Defense Health Agency (DHA), underscore the market's adoption of its Converge platform. However, investors should note the persistent decline in visit volumes, a projected sequential widening of EBITDA losses in Q3, and a significant revenue concentration with the DHA, whose contract renewal is deemed essential for long-term stability.

Key Decisions for Investors

• Investors should prioritize tracking the growth of high-margin subscription revenue and gross margin expansion over top-line revenue, as the market is positively valuing the company's strategic shift to a more profitable software-as-a-service model.
• While the progress towards profitability is a strong bullish signal, it is critical to monitor the company's execution against its 2026 positive operating cash flow target, especially given the anticipated sequential widening of the adjusted EBITDA loss in Q3 2025.
• Factor in the significant client concentration risk tied to the Defense Health Agency (DHA) contract, as its future renewal represents a critical catalyst and potential point of vulnerability for the company's revenue stability.